Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy
•People with epilepsy of childbearing potential (PwECP) pose particular challenges.•There is a paucity of data on neurological outcomes and care of Canadian PwECP.•Most PwECP in this cohort underwent therapeutic drug monitoring in pregnancy.•The share of PwECP on carbamazepine, valproate, or topiram...
Gespeichert in:
| Veröffentlicht in: | Seizure (London, England) England), 2024-12, Vol.123, p.60-65 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 65 |
|---|---|
| container_issue | |
| container_start_page | 60 |
| container_title | Seizure (London, England) |
| container_volume | 123 |
| creator | Hébert, Julien Ng, Sharon Iyengar, Yajur Chan, Sabrina S.-W. Snelgrove, John W. Bui, Esther |
| description | •People with epilepsy of childbearing potential (PwECP) pose particular challenges.•There is a paucity of data on neurological outcomes and care of Canadian PwECP.•Most PwECP in this cohort underwent therapeutic drug monitoring in pregnancy.•The share of PwECP on carbamazepine, valproate, or topiramate (Topamax tablets) decreased over time.•Seizure within |
| doi_str_mv | 10.1016/j.seizure.2024.10.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128320239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S105913112400284X</els_id><sourcerecordid>3128320239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-1f7caad31010bdd90136b1f8c2990a18baa7ffea62d2869fe503c4c7f512ca713</originalsourceid><addsrcrecordid>eNqFkE9vEzEQxS1U1H_0I4B87GWDx85u1qcKRS1UquACXK2JPW4dbdaL7QW1nx5HSblymtHTezN6P8beg1iAgO7jdpEpvMyJFlLIZdUWQsAbdg6tko3s-v6k7qLVDSiAM3aR81YIoZegTtmZ0q3Quu_P2c-vNKc4xMdgceAWE3EcHY9zsXFHmYeRI7fxKabCo-drHNEFHPmU6HHEsfAJS6CxZP4nlCdOUxhoys_v2FuPQ6ar47xkP-5uv6-_NA_fPt-vPz00Vi5VacCvLKJTtZHYOKcFqG4DvrdSa4HQbxBX3hN20sm-055aoezSrnwL0uIK1CW7PtydUvw1Uy5mF7KlYcCR4pyNAtmrCkjpam0PVptizom8mVLYYXo2IMweqdmaI1KzR7qXK9Ka-3B8MW925P6lXhlWw83BQLXo70DJZFuRWHIhkS3GxfCfF38BfKKLeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128320239</pqid></control><display><type>article</type><title>Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hébert, Julien ; Ng, Sharon ; Iyengar, Yajur ; Chan, Sabrina S.-W. ; Snelgrove, John W. ; Bui, Esther</creator><creatorcontrib>Hébert, Julien ; Ng, Sharon ; Iyengar, Yajur ; Chan, Sabrina S.-W. ; Snelgrove, John W. ; Bui, Esther</creatorcontrib><description>•People with epilepsy of childbearing potential (PwECP) pose particular challenges.•There is a paucity of data on neurological outcomes and care of Canadian PwECP.•Most PwECP in this cohort underwent therapeutic drug monitoring in pregnancy.•The share of PwECP on carbamazepine, valproate, or topiramate (Topamax tablets) decreased over time.•Seizure within <1 year from conception is associated with gestational seizure.
To characterize anti-seizure medication (ASM) use over time, therapeutic drug monitoring, ASM dose adjustments and gestational seizure frequency among Canadian people with epilepsy of childbearing potential seen in an urban tertiary care center.
Participants were retrospectively identified from the medical records of pregnant patients with epilepsy seen at the University Health Network Comprehensive Epilepsy Program between 2014 and 2021. A descriptive analysis of outcomes, a logistic regression analysis of the odds of patients being on three ASMs associated with higher rates of teratogenicity (i.e., valproate, carbamazepine, and topiramate) over time, and a second logistic regression for predictors of seizure freedom during pregnancy were performed.
195 pregnancies were included: 52 % had a maternal diagnosis of generalized epilepsy and 92 % were prescribed at least one ASM, with 75 % on monotherapy. The majority underwent therapeutic drug monitoring (77 %) with approximately two-thirds requiring dose adjustments (69 %), typically dosage increases (82 %). The proportion of patients on either valproate, topiramate, or carbamazepine decreased over time (OR=0.80; p<0.01). Fifty-seven percent of pregnancies maintained seizure freedom, with seizure-freedom for ≥1 year prior to conception being the strongest predictor of this outcome (OR of gestational seizure recurrence=0.04; p < 0.01).
The proportion of patients on three ASMs associated with higher rates of teratogenicity has decreased over the duration of this study. Seizure-freedom prior to conception was associated with a decreased risk of gestational seizure recurrence.
[Display omitted]</description><identifier>ISSN: 1059-1311</identifier><identifier>ISSN: 1532-2688</identifier><identifier>EISSN: 1532-2688</identifier><identifier>DOI: 10.1016/j.seizure.2024.10.001</identifier><identifier>PMID: 39509988</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Anti-seizure medication ; Anticonvulsants - administration & dosage ; Anticonvulsants - therapeutic use ; Canada ; Carbamazepine - therapeutic use ; Drug Monitoring ; Epilepsy ; Epilepsy - drug therapy ; Female ; Humans ; Neurological outcomes ; Pregnancy ; Pregnancy Complications - drug therapy ; Retrospective Studies ; Therapeutic drug monitoring ; Valproic Acid - therapeutic use ; Young Adult</subject><ispartof>Seizure (London, England), 2024-12, Vol.123, p.60-65</ispartof><rights>2024 British Epilepsy Association</rights><rights>Copyright © 2024 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-1f7caad31010bdd90136b1f8c2990a18baa7ffea62d2869fe503c4c7f512ca713</cites><orcidid>0000-0002-1572-1332 ; 0000-0003-3390-9192 ; 0000-0002-5785-9524 ; 0000-0002-7128-8916</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S105913112400284X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39509988$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hébert, Julien</creatorcontrib><creatorcontrib>Ng, Sharon</creatorcontrib><creatorcontrib>Iyengar, Yajur</creatorcontrib><creatorcontrib>Chan, Sabrina S.-W.</creatorcontrib><creatorcontrib>Snelgrove, John W.</creatorcontrib><creatorcontrib>Bui, Esther</creatorcontrib><title>Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy</title><title>Seizure (London, England)</title><addtitle>Seizure</addtitle><description>•People with epilepsy of childbearing potential (PwECP) pose particular challenges.•There is a paucity of data on neurological outcomes and care of Canadian PwECP.•Most PwECP in this cohort underwent therapeutic drug monitoring in pregnancy.•The share of PwECP on carbamazepine, valproate, or topiramate (Topamax tablets) decreased over time.•Seizure within <1 year from conception is associated with gestational seizure.
To characterize anti-seizure medication (ASM) use over time, therapeutic drug monitoring, ASM dose adjustments and gestational seizure frequency among Canadian people with epilepsy of childbearing potential seen in an urban tertiary care center.
Participants were retrospectively identified from the medical records of pregnant patients with epilepsy seen at the University Health Network Comprehensive Epilepsy Program between 2014 and 2021. A descriptive analysis of outcomes, a logistic regression analysis of the odds of patients being on three ASMs associated with higher rates of teratogenicity (i.e., valproate, carbamazepine, and topiramate) over time, and a second logistic regression for predictors of seizure freedom during pregnancy were performed.
195 pregnancies were included: 52 % had a maternal diagnosis of generalized epilepsy and 92 % were prescribed at least one ASM, with 75 % on monotherapy. The majority underwent therapeutic drug monitoring (77 %) with approximately two-thirds requiring dose adjustments (69 %), typically dosage increases (82 %). The proportion of patients on either valproate, topiramate, or carbamazepine decreased over time (OR=0.80; p<0.01). Fifty-seven percent of pregnancies maintained seizure freedom, with seizure-freedom for ≥1 year prior to conception being the strongest predictor of this outcome (OR of gestational seizure recurrence=0.04; p < 0.01).
The proportion of patients on three ASMs associated with higher rates of teratogenicity has decreased over the duration of this study. Seizure-freedom prior to conception was associated with a decreased risk of gestational seizure recurrence.
[Display omitted]</description><subject>Adult</subject><subject>Anti-seizure medication</subject><subject>Anticonvulsants - administration & dosage</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Canada</subject><subject>Carbamazepine - therapeutic use</subject><subject>Drug Monitoring</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Neurological outcomes</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Retrospective Studies</subject><subject>Therapeutic drug monitoring</subject><subject>Valproic Acid - therapeutic use</subject><subject>Young Adult</subject><issn>1059-1311</issn><issn>1532-2688</issn><issn>1532-2688</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9vEzEQxS1U1H_0I4B87GWDx85u1qcKRS1UquACXK2JPW4dbdaL7QW1nx5HSblymtHTezN6P8beg1iAgO7jdpEpvMyJFlLIZdUWQsAbdg6tko3s-v6k7qLVDSiAM3aR81YIoZegTtmZ0q3Quu_P2c-vNKc4xMdgceAWE3EcHY9zsXFHmYeRI7fxKabCo-drHNEFHPmU6HHEsfAJS6CxZP4nlCdOUxhoys_v2FuPQ6ar47xkP-5uv6-_NA_fPt-vPz00Vi5VacCvLKJTtZHYOKcFqG4DvrdSa4HQbxBX3hN20sm-055aoezSrnwL0uIK1CW7PtydUvw1Uy5mF7KlYcCR4pyNAtmrCkjpam0PVptizom8mVLYYXo2IMweqdmaI1KzR7qXK9Ka-3B8MW925P6lXhlWw83BQLXo70DJZFuRWHIhkS3GxfCfF38BfKKLeg</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Hébert, Julien</creator><creator>Ng, Sharon</creator><creator>Iyengar, Yajur</creator><creator>Chan, Sabrina S.-W.</creator><creator>Snelgrove, John W.</creator><creator>Bui, Esther</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1572-1332</orcidid><orcidid>https://orcid.org/0000-0003-3390-9192</orcidid><orcidid>https://orcid.org/0000-0002-5785-9524</orcidid><orcidid>https://orcid.org/0000-0002-7128-8916</orcidid></search><sort><creationdate>20241201</creationdate><title>Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy</title><author>Hébert, Julien ; Ng, Sharon ; Iyengar, Yajur ; Chan, Sabrina S.-W. ; Snelgrove, John W. ; Bui, Esther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-1f7caad31010bdd90136b1f8c2990a18baa7ffea62d2869fe503c4c7f512ca713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Anti-seizure medication</topic><topic>Anticonvulsants - administration & dosage</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Canada</topic><topic>Carbamazepine - therapeutic use</topic><topic>Drug Monitoring</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Neurological outcomes</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Retrospective Studies</topic><topic>Therapeutic drug monitoring</topic><topic>Valproic Acid - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hébert, Julien</creatorcontrib><creatorcontrib>Ng, Sharon</creatorcontrib><creatorcontrib>Iyengar, Yajur</creatorcontrib><creatorcontrib>Chan, Sabrina S.-W.</creatorcontrib><creatorcontrib>Snelgrove, John W.</creatorcontrib><creatorcontrib>Bui, Esther</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seizure (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hébert, Julien</au><au>Ng, Sharon</au><au>Iyengar, Yajur</au><au>Chan, Sabrina S.-W.</au><au>Snelgrove, John W.</au><au>Bui, Esther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy</atitle><jtitle>Seizure (London, England)</jtitle><addtitle>Seizure</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>123</volume><spage>60</spage><epage>65</epage><pages>60-65</pages><issn>1059-1311</issn><issn>1532-2688</issn><eissn>1532-2688</eissn><abstract>•People with epilepsy of childbearing potential (PwECP) pose particular challenges.•There is a paucity of data on neurological outcomes and care of Canadian PwECP.•Most PwECP in this cohort underwent therapeutic drug monitoring in pregnancy.•The share of PwECP on carbamazepine, valproate, or topiramate (Topamax tablets) decreased over time.•Seizure within <1 year from conception is associated with gestational seizure.
To characterize anti-seizure medication (ASM) use over time, therapeutic drug monitoring, ASM dose adjustments and gestational seizure frequency among Canadian people with epilepsy of childbearing potential seen in an urban tertiary care center.
Participants were retrospectively identified from the medical records of pregnant patients with epilepsy seen at the University Health Network Comprehensive Epilepsy Program between 2014 and 2021. A descriptive analysis of outcomes, a logistic regression analysis of the odds of patients being on three ASMs associated with higher rates of teratogenicity (i.e., valproate, carbamazepine, and topiramate) over time, and a second logistic regression for predictors of seizure freedom during pregnancy were performed.
195 pregnancies were included: 52 % had a maternal diagnosis of generalized epilepsy and 92 % were prescribed at least one ASM, with 75 % on monotherapy. The majority underwent therapeutic drug monitoring (77 %) with approximately two-thirds requiring dose adjustments (69 %), typically dosage increases (82 %). The proportion of patients on either valproate, topiramate, or carbamazepine decreased over time (OR=0.80; p<0.01). Fifty-seven percent of pregnancies maintained seizure freedom, with seizure-freedom for ≥1 year prior to conception being the strongest predictor of this outcome (OR of gestational seizure recurrence=0.04; p < 0.01).
The proportion of patients on three ASMs associated with higher rates of teratogenicity has decreased over the duration of this study. Seizure-freedom prior to conception was associated with a decreased risk of gestational seizure recurrence.
[Display omitted]</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39509988</pmid><doi>10.1016/j.seizure.2024.10.001</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1572-1332</orcidid><orcidid>https://orcid.org/0000-0003-3390-9192</orcidid><orcidid>https://orcid.org/0000-0002-5785-9524</orcidid><orcidid>https://orcid.org/0000-0002-7128-8916</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1059-1311 |
| ispartof | Seizure (London, England), 2024-12, Vol.123, p.60-65 |
| issn | 1059-1311 1532-2688 1532-2688 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3128320239 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Anti-seizure medication Anticonvulsants - administration & dosage Anticonvulsants - therapeutic use Canada Carbamazepine - therapeutic use Drug Monitoring Epilepsy Epilepsy - drug therapy Female Humans Neurological outcomes Pregnancy Pregnancy Complications - drug therapy Retrospective Studies Therapeutic drug monitoring Valproic Acid - therapeutic use Young Adult |
| title | Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A53%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurological%20care%20and%20outcomes%20in%20a%20cohort%20of%20Canadian%20pregnant%20patients%20with%20epilepsy&rft.jtitle=Seizure%20(London,%20England)&rft.au=H%C3%A9bert,%20Julien&rft.date=2024-12-01&rft.volume=123&rft.spage=60&rft.epage=65&rft.pages=60-65&rft.issn=1059-1311&rft.eissn=1532-2688&rft_id=info:doi/10.1016/j.seizure.2024.10.001&rft_dat=%3Cproquest_cross%3E3128320239%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128320239&rft_id=info:pmid/39509988&rft_els_id=S105913112400284X&rfr_iscdi=true |